SCHEMBL830134

SCHEMBL830134

Nc1ccc(OCC(=O)OCCOC(=O)COc2ccc(N)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 3/20 0.47
TSHR P16473 1/20 0.45
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
HSD17B10 Q99714 2/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
APP P05067 1/20 0.44
TBXAS1 P24557 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16261830 0.95 APP (0.51) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL831493 0.91 APP (0.51) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL13056613 0.90 GAA (0.49) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL17083543 0.90 LMNA (0.58) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL27483976 0.88 CYP1A2 (0.59) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL16270203 0.87 GAA (0.50) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL16270513 0.86 APP (0.54) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL654389 0.85 GAA (0.66) SMN1; SMN2CYP1A2CYP3A4NPC1RAB9A
SCHEMBL829668 0.85 TDP1 (0.46) SMN1; SMN2CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL8625200 0.84 NPC1 (0.60) CYP1A2CYP3A4CYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11116866-B2 Multi-putty adhesive and cement compositions for tissue hemostasis, repair and reconstruction ABYRX, INC. (US) 2021-09-14 US disclosed
US-20200061236-A1 MULTI-PUTTY ADHESIVE AND CEMENT COMPOSITIONS FOR TISSUE HEMOSTASIS, REPAIR AND RECONSTRUCTION ORTHOCON, INC. 2020-02-27 US disclosed
US-20190099514-A1 MULTI-PUTTY ADHESIVE AND CEMENT COMPOSITIONS FOR TISSUE HEMOSTASIS, REPAIR AND RECONSTRUCTION ORTHOCON, INC. 2019-04-04 US disclosed
US-20160250374-A1 Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use ORTHOCON, INC. 2016-09-01 US disclosed
US-20160250374-A1 Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use ORTHOCON, INC. 2016-09-01 US disclosed
US-9314547-B2 Absorbable multi-putty bone cements and hemostatic compositions and methods of use ABYRX INC. (US) 2016-04-19 US disclosed
US-9314547-B2 Absorbable multi-putty bone cements and hemostatic compositions and methods of use ABYRX INC. (US) 2016-04-19 US disclosed
US-20160023998-A1 HYDROLYSABLE LINKERS AND CROSS-LINKERS FOR ABSORBABLE POLYMERS BEZWADA BIOMEDICAL LLC (US) 2016-01-28 US disclosed
US-20160023998-A1 HYDROLYSABLE LINKERS AND CROSS-LINKERS FOR ABSORBABLE POLYMERS BEZWADA BIOMEDICAL LLC (US) 2016-01-28 US disclosed
US-20160023998-A1 HYDROLYSABLE LINKERS AND CROSS-LINKERS FOR ABSORBABLE POLYMERS BEZWADA BIOMEDICAL LLC (US) 2016-01-28 US disclosed
US-20090060979-A1 CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS BEZWADA BIOMEDICAL, LLC 2009-03-05 US disclosed
US-20090060979-A1 CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS BEZWADA BIOMEDICAL, LLC 2009-03-05 US disclosed
EP-1937182-A2 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES Bezwada Biomedical LLC (US) 2008-07-02 EP disclosed
EP-1931334-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM Bezwada Biomedical LLC (US) 2008-06-18 EP disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030464-A2 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030464-A2 BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
US-20060188547-A1 Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices BEZWADA BIOMEDICAL, LLC (US) 2006-08-24 US disclosed
US-20060172983-A1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160023998-A1 HYDROLYSABLE LINKERS AND CROSS-LINKERS FOR ABSORBABLE POLYMERS SI, KDM8, APEH SMN1; SMN2 3337/4885CYP1A2 1323/4885CYP3A4 1200/4885
US-20090060979-A1 CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS GUSB, BMP2, APEH SMN1; SMN2 4617/4885CYP1A2 749/4885CYP3A4 457/4885
US-20060172983-A1 Functionalized drugs and polymers derived therefrom OGFR, LOX, OPRM1 SMN1; SMN2 3370/4885CYP1A2 1930/4885CYP3A4 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.